@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_head { this: np:hasAssertion dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_assertion; np:hasProvenance dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_provenance; np:hasPublicationInfo dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_publicationInfo; a np:Nanopublication . dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_assertion a np:Assertion . dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_provenance a np:Provenance . dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_publicationInfo a np:PublicationInfo . } dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_assertion { miriam-gene:100 a ncit:C16612 . lld:C0023443 a ncit:C7057 . dgn-gda:DGN3b6c20517b843ca28df8dc53842753c9 sio:SIO_000628 miriam-gene:100, lld:C0023443; a sio:SIO_001121 . } dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_provenance { dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_assertion dcterms:description "[Examples of new agents are: trastuzumab (Herceptin), a humanized monoclonal antibody that blocks the HER-2/neu proto-oncogene in combination with cytotoxic agents, is used in a percentage of breast cancer patients; signal transduction inhibitor of abl tyrosine kinase STI 571 (Glivec) has been shown to be an active treatment for chronic myeloid leukemia and GISTs; epidermal growth factor receptors in certain tumors have been targeted with agents such as C225 (Cetuximab) and ZD 1839 (IRESSA); an adenosine deaminase analogue of deoxyadenosine, Cladribine (2-chloro-2 deoxy-adenosine) has shown high effectiveness in hairy-cell leukemia and the multitargeted antifolate (Premetrexed) and several vaccines have been studied and are in clinical trials for resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:12375030; prov:wasDerivedFrom dgn-void:befree-20140225; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP721390.RA6e7Abin0N4k8x2TjHi8Dqx4yMq8cGqxAY-gUte62sto130_publicationInfo { this: dcterms:created "2014-10-02T12:39:18+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }